NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary cancers, version 2.2021 Guidelines

  


Authors: Benson, A. B. 3rd; D'Angelica, M. I.; Abbott, D. E.; Anaya, D. A.; Anders, R.; Are, C.; Bachini, M.; Borad, M.; Brown, D.; Burgoyne, A.; Chahal, P.; Chang, D. T.; Cloyd, J.; Covey, A. M.; Glazer, E. S.; Goyal, L.; Hawkins, W. G.; Iyer, R.; Jacob, R.; Kelley, R. K.; Kim, R.; Levine, M.; Palta, M.; Park, J. O.; Raman, S.; Reddy, S.; Sahai, V.; Schefter, T.; Singh, G.; Stein, S.; Vauthey, J. N.; Venook, A. P.; Yopp, A.; McMillian, N. R.; Hochstetler, C.; Darlow, S. D.
Title: NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary cancers, version 2.2021
Abstract: The NCCN Guidelines for Hepatobiliary Cancers focus on the screening, diagnosis, staging, treatment, and management of hepatocellular carcinoma (HCC), gallbladder cancer, and cancer of the bile ducts (intrahepatic and extrahepatic cholangiocarcinoma). Due to the multiple modalities that can be used to treat the disease and the complications that can arise from comorbid liver dysfunction, a multidisciplinary evaluation is essential for determining an optimal treatment strategy. A multidisciplinary team should include hepatologists, diagnostic radiologists, interventional radiologists, surgeons, medical oncologists, and pathologists with hepatobiliary cancer expertise. In addition to surgery, transplant, and intra-arterial therapies, there have been great advances in the systemic treatment of HCC. Until recently, sorafenib was the only systemic therapy option for patients with advanced HCC. In 2020, the combination of atezolizumab and bevacizumab became the first regimen to show superior survival to sorafenib, gaining it FDA approval as a new frontline standard regimen for unresectable or metastatic HCC. This article discusses the NCCN Guidelines recommendations for HCC. © 2021 Harborside Press. All rights reserved.
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 19
Issue: 5
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2021-05-01
Start Page: 541
End Page: 565
Language: English
DOI: 10.6004/jnccn.2021.0022
PUBMED: 34030131
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85106858883&doi=10.6004%2fjnccn.2021.0022&partnerID=40&md5=c69bbdf0c0579c410041605b4a51d9c5
Notes: Review -- Export Date: 1 July 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Anne Covey
    165 Covey
  2. Michael D'Angelica
    777 D'Angelica
Related MSK Work